What will it take to thaw the frozen HealthTech and Digital Health markets beyond the Hinge Health IPO?

Lloyd Price
53 minutes ago
8 min read

What will it take to thaw the frozen HealthTech market beyond the Hinge Health IPO?

The HealthTech market has been cautious since the 2021 IPO wave underperformed, with Hinge Health’s 2025 IPO signalling a potential shift. To fully thaw the market and spur broader activity beyond this milestone, several key factors need to align, based on current trends and dynamics:

Improved Macroeconomic Conditions: A stable economy with lower interest rates and reduced market volatility is critical. The Federal Reserve’s easing of rates and resolution of uncertainties, like the 2024 U.S. presidential election, could boost investor confidence. A stronger global economy, projected to grow the healthcare market by 5.4% annually through 2028, will create demand for HealthTech solutions, encouraging IPOs.
Strong Company Fundamentals: HealthTech startups must demonstrate robust financials—revenue in the hundreds of millions, 30%+ year-over-year growth, and clear paths to profitability. Hinge Health’s $390M revenue and 77% gross margin in 2024 set a benchmark. Companies like Omada Health, Sword Health, or Doctolib, with scalable models in digital health or SaaS, are well-positioned if they mirror these metrics.
Investor Appetite for Innovation: Continued focus on transformative technologies like AI, telemedicine, and remote monitoring will drive interest. AI-focused HealthTech firms, commanding 38% of sector investments in 2024, are seeing valuations 2-5x higher than non-AI peers. Investors favor companies with clinical-grade AI, personalised care, or data analytics that improve outcomes and efficiency.
Favourable Regulatory Environment: Supportive policies, like those prioritising healthcare innovation
under the Biden administration, reduce barriers. Regulatory clarity around telehealth, data privacy, and reimbursement for digital solutions will encourage market entry. Governments promoting EHR adoption and AI integration, as seen in North America and Asia-Pacific, further support growth.
Successful IPO Precedents: Hinge Health’s IPO, targeting a $2.98B valuation, must perform strongly to rebuild trust after 2021’s lackluster HealthTech IPOs. If it achieves solid post-IPO performance, it could pave the way for others like Aledade or Quantum Health. A wave of successful IPOs in adjacent sectors (e.g., biotech, fintech) could also signal a broader market reopening.
M&A as a Catalyst: With IPO exits challenging, increased M&A activity could stimulate the market. Strategic acquisitions by large pharma or tech firms, like Biogen’s 2024 purchase of Human Immunology Biosciences, signal portfolio optimization. HealthTech firms offering efficiencies in telehealth or analytics are prime targets, potentially unlocking capital for new investments.
Focus on Value-Based Care: Demand for solutions that support value-based care—rewarding quality over cost—is rising. HealthTech firms providing data-driven tools for outcome tracking, patient engagement, or cost reduction will attract investors. This aligns with the growing importance of analytics in healthcare delivery.

Challenges like high deployment costs, data privacy concerns, and competitive saturation could slow progress. Companies must address these through efficient unit economics and compliance with regulations like HIPAA. The HealthTech market, valued at $908.5B in 2023 and projected to reach $3,140.9B by 2033, has strong fundamentals, but thawing requires sustained momentum in these areas to rebuild investor trust and drive listings

Why are the healthtech and digital markets frozen?

The HealthTech and Digital Health markets have experienced a significant cooling down period after a series of boom years during the pandemic. Several factors contribute to this shift:

1. Investment Correction and Market Reset

Overvaluation: During the pandemic, there was a surge of investment into digital health, leading to inflated valuations for many companies. This was fueled by a perceived rapid acceleration of digital adoption and telehealth.

"Venture Capital Winter": The broader venture capital landscape has tightened significantly. Higher interest rates, inflation concerns, and a shift away from growth-at-all-costs mentalities have led VCs to be more cautious with their investments. This impacts all sectors, including HealthTech.

Focus on Profitability: Investors are now prioritising profitability and sustainable business models over rapid growth. Many digital health companies that scaled quickly during the pandemic are now being pressed to demonstrate clear paths to profitability.

2. Post-Pandemic Normalisation

Telehealth Plateau: While telehealth adoption remains higher than pre-pandemic levels, the explosive growth has plateaued. Some in-person care has resumed, and the novelty of telehealth has worn off for some patients and providers.

Return to Traditional Care: As healthcare systems stabilised, there's been a partial return to traditional care pathways, which can sometimes compete with or slow the adoption of purely digital solutions.

3. Regulatory and Reimbursement Uncertainty

Evolving Regulations: The regulatory landscape for digital health is still evolving. Uncertainty around data privacy (e.g., HIPAA enforcement for new digital tools), digital therapeutics approval pathways, and cross-state licensure for telehealth can deter investment and slow adoption.

Reimbursement Challenges: Consistent and favourable reimbursement for digital health services remains a hurdle.While temporary flexibilities were introduced during the pandemic, permanent policies are still being debated and implemented, creating financial uncertainty for providers relying on these services.

4. Market Saturation and Differentiation

Crowded Landscape: The pandemic led to a proliferation of digital health solutions across various categories (telemedicine, remote monitoring, mental health apps, etc.). This has created a crowded market where it's harder for new entrants to differentiate themselves and gain market share.

Lack of Clear ROI: Some digital health solutions struggle to demonstrate a clear return on investment (ROI) for payers, providers, or even patients, making it difficult to justify their cost.

5. Integration and Interoperability Issues

Fragmented Ecosystem: The healthcare IT landscape is notoriously fragmented. Integrating new digital health solutions with existing electronic health records (EHRs) and other legacy systems can be complex, time-consuming, and expensive, hindering widespread adoption.

Data Silos: Lack of interoperability between different digital health platforms and healthcare systems creates data silos, preventing a holistic view of patient health and hindering efficient care coordination.

6. User Engagement and Adoption

Patient Engagement Challenges: While many digital health tools exist, sustained patient engagement can be a challenge. Issues like digital literacy, access to broadband, and a preference for in-person interactions can limit the reach and effectiveness of some solutions.

Provider Workflow Integration: Digital health tools need to seamlessly integrate into provider workflows. If they add complexity or burden, adoption can be slow.

In summary, the "cooling" in the HealthTech and digital health markets is a multifaceted issue driven by a combination of macro-economic factors, a post-pandemic market correction, ongoing regulatory and reimbursement challenges, and the inherent complexities of healthcare innovation and adoption. It's a period of recalibration, where the focus is shifting towards proven value, profitability, and sustainable growth. While the rapid influx of capital has slowed, many believe this period of consolidation and increased scrutiny will ultimately lead to a more mature and robust HealthTech ecosystem in the long run.

When are the healthtech and digital markets likely to melt and start being active again?

Predicting when the HealthTech and digital health markets will fully "thaw" and regain robust activity is complex, but based on current trends, market dynamics, and expert analyses, a meaningful recovery is likely to begin in mid-to-late 2025, with full momentum potentially building into 2026-2027.

Here’s a breakdown of the timeline and key drivers:

Timeline for Recovery

Mid-2025: Early Thaw

Hinge Health IPO as a Catalyst: Hinge Health’s planned 2025 IPO, targeting a $2.98B valuation, could set the tone. A successful debut with strong post-IPO performance (e.g., stable or rising stock price) could signal to investors that HealthTech is viable again, encouraging other companies like Omada Health or Sword Health to follow.

Macroeconomic Stabilisation: With the Federal Reserve easing interest rates (projected to stabilize around 3-4% by mid-2025) and post-2024 election clarity reducing policy uncertainty, investor risk appetite should improve. This aligns with forecasts of global healthcare market growth at 5.4% annually through 2028.

AI and Innovation Momentum: AI-driven HealthTech, which captured 38% of sector investments in 2024, will continue to draw interest. Companies leveraging clinical-grade AI or data analytics for personalised care or cost reduction are likely to lead early activity.
2026: Broader Activity

Wave of IPOs and M&A: If Hinge Health and 1-2 other HealthTech IPOs succeed in 2025, a wave of IPOs could follow in 2026, particularly for companies with strong fundamentals (e.g., $100M+ ARR, 30%+ YoY growth). Increased M&A activity, as seen with Biogen’s 2024 acquisition of Human Immunology Biosciences, will also unlock capital and stimulate investment.

Regulatory Tailwinds: Ongoing policy support for telehealth, value-based care, and EHR adoption (especially in North America and Asia-Pacific) will reduce barriers, enabling faster scaling for digital health firms.

Investor Confidence Rebound: As macroeconomic conditions improve and successful exits demonstrate viability, venture capital and private equity funding, which dropped to $10.7B in 2023, could rebound to 2021 levels ($29.1B) by 2026.
2027 and Beyond: Full Momentum

The HealthTech market, valued at $908.5B in 2023 and projected to reach $3,140.9B by 2033, will see sustained growth as digital adoption becomes standard in healthcare. Companies addressing high-demand areas like chronic disease management, remote monitoring, and mental health will drive activity.

Consolidation in saturated sub-sectors (e.g., telehealth) will clear out weaker players, allowing differentiated firms to capture market share and investor interest.

Key Drivers for Melting the Market

Economic Recovery: Lower interest rates and reduced volatility will encourage risk-taking in public and private markets.
Proven Business Models: Companies must show profitability or near-term paths to it, with metrics like Hinge Health’s $390M revenue and 77% gross margin as benchmarks.
Technological Differentiation: AI, machine learning, and analytics-driven solutions will attract higher valuations (2-5x non-AI peers), pulling capital into the sector.
Policy Support: Clearer reimbursement policies and regulatory frameworks for digital health will boost adoption by providers and payers.
Successful Exits: A few strong IPOs or high-profile acquisitions will rebuild trust, encouraging more companies to go public or seek strategic buyers.

Potential Risks Delaying Recovery

Economic Relapse: Persistent inflation or geopolitical instability could delay investor confidence.
Regulatory Setbacks: Stricter data privacy laws or reimbursement challenges could slow adoption.
Underperforming IPOs: If Hinge Health or early 2025 IPOs falter, it could prolong the freeze, as seen post-2021.
Market Saturation: Overcrowding in sub-sectors like mental health apps could suppress valuations unless companies differentiate.

The HealthTech and digital health markets are poised to begin thawing in mid-2025, driven by Hinge Health’s IPO, improving economic conditions, and AI-driven innovation. Broader activity, including multiple IPOs and increased M&A, is likely in 2026, with full momentum by 2027 if fundamentals and investor trust align. However, risks like economic volatility or regulatory hurdles could push this timeline out, requiring companies to focus on profitability and differentiation to capitalise on the recovery.

Nelson Advisors > Healthcare Technology M&A

Nelson Advisors specialise in mergers, acquisitions & partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

We share our views on the latest Healthcare Technology mergers, acquisitions & partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide